Evidence map›Paper›PMID 23404351›Full record

ArticleGenes, chromosomes & cancer2013

Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia.

Sarah E Kleinstein, Laura Heath, Karen W Makar, Elizabeth M Poole, Brenna L Seufert, Martha L Slattery, Liren Xiao, David J Duggan, Li Hsu, Karen Curtin and 7 more

Open access · greenAbstract read
In one paragraph

Article in Genes, chromosomes & cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Genetic Variants inFrontiers in oncology · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

Sarah E KleinsteinCancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Laura Heath
Karen W Makar
Elizabeth M Poole
Brenna L Seufert
Martha L Slattery
Liren Xiao
David J Duggan
Li Hsu
Karen Curtin
Lisel Koepl
Jill Muehling
Darin Taverna
Bette J Caan
Christopher S Carlson
John D Potter
Cornelia M Ulrich
Fred Hutch Cancer Center · USTranslational Genomics Research Institute · USUniversity of Utah · USHarvard University · USHeidelberg University · DEKaiser Permanente · USUniversity of Washington · US

Funding

Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
Use of Biomarkers in Diagnosis, Prognosis, Risk Prediction and Early Detection ofP01CA053996 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HSU, LI · 1991 to 2015
$9.4M
DIET, ACTIVITY &REPRODUCTION--RISKS FOR RECTAL CANCERR01CA048998 · NCI · UNIVERSITY OF UTAH · PI SLATTERY, MARTHA L · 1991 to 2012
$7.9M
Cancer Prevention Trng-Nutrition, Exercise &GeneticsR25CA094880 · NCI · UNIVERSITY OF WASHINGTON · PI WHITE, EMILY · 2002 to 2016
$7.3M
Prostaglandin Synthesis, Genetics and Colorectal CancerR01CA114467 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ULRICH, CORNELIA M · 2006 to 2010
$2.7M
Statistical Methods in Genetic EpidemiologyR01AG014358 · NIA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HSU, LI · 2002 to 2013
$2.4M
Genetic Study of Prostaglandin Synthesis/EGFR and Risk of Colorectal NeoplasiaR03CA123577 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ULRICH, CORNELIA M · 2006 to 2007
$170k
DIET, ACTIVITY &REPRODUCTION--RISKS FOR RECTAL CANCERU01CA048998 · NCI · UNIVERSITY OF UTAH · PI SLATTERY, MARTHA OR MARTY L · 1997 to 1999
–
NCI NIH HHS CA48998NCI NIH HHS P01 CA053996NCI NIH HHS R01 CA048998NCI NIH HHS R01 CA114467NCI NIH HHS R03 CA123577NCI NIH HHS R25 CA094880NCI NIH HHS T32 CA009001NCI NIH HHS U01 CA048998NIA NIH HHS R01 AG014358
6 · The paper itself

Abstract

Arachidonate lipoxygenase (ALOX) enzymes metabolize arachidonic acid to generate potent inflammatory mediators and play an important role in inflammation-associated diseases. We investigated associations between colorectal cancer risk and polymorphisms in ALOX5, FLAP, ALOX12, and ALOX15, and their interactions with nonsteroidal anti-inflammatory drug (NSAID) use. We genotyped fifty tagSNPs, one candidate SNP, and two functional promoter variable nucleotide tandem repeat (VNTR) polymorphisms in three US population-based case-control studies of colon cancer (1,424 cases/1,780 controls), rectal cancer (583 cases/775 controls), and colorectal adenomas (485 cases/578 controls). Individuals with variant genotypes of the ALOX5 VNTR had a decreased risk of rectal cancer, with the strongest association seen for individuals with one or more alleles of >5 repeats (wild type = 5, OR>5/≥5 = 0.42, 95% CI 0.20-0.92; P = 0.01). Four SNPs in FLAP (rs17239025), ALOX12 (rs2073438), and ALOX15 (rs4796535 and rs2619112) were associated with rectal cancer risk at P ≤ 0.05. One SNP in FLAP (rs12429692) was associated with adenoma risk. A false discovery rate (FDR) was applied to account for false positives due to multiple testing; the ALOX15 associations were noteworthy at 25% FDR. Colorectal neoplasia risk appeared to be modified by NSAID use in individuals with variant alleles in FLAP and ALOX15. One noteworthy interaction (25% FDR) was observed for rectal cancer. Genetic variability in ALOXs may affect risk of colorectal neoplasia, particularly for rectal cancer. Additionally, genetic variability in FLAP and ALOX15 may modify the protective effect of NSAID use against colorectal neoplasia.

Indexed as

Polymorphism, Single Nucleotide5-Lipoxygenase-Activating ProteinsAdenomaAdultAgedAnticarcinogenic AgentsAnti-Inflammatory Agents, Non-SteroidalArachidonate 12-LipoxygenaseArachidonate 15-LipoxygenaseArachidonate 5-LipoxygenaseCase-Control StudiesColorectal NeoplasmsFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumans5-Lipoxygenase-Activating ProteinsALOX12 protein, humanALOX15 protein, humanALOX5AP protein, humanAnticarcinogenic AgentsAnti-Inflammatory Agents, Non-SteroidalArachidonate 12-LipoxygenaseArachidonate 15-LipoxygenaseArachidonate 5-Lipoxygenase

Identifiers

PMID23404351
PMCPMC3698944
OpenAlexW2057133574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.